2018 (иностранная)

Logo1

Публикации членов общества на иностранном языке
Zastrozhin MS., Sorokin AS., Agibalova AV., et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers Human Psychopharmacology: Clinical and Experimental.2018;e2677, 8.
Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and Personalized Medicine 2018:11;113—119.
Zastrozhin MS, Antonenko AP, Nesterenko EV, et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018 Oct
Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-54.
Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty Pharmacogenomics and Personalized Me
Sychev DA, Ashraf GM, Svistunov AA, et al. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Design, Development and Therapy. 2018:12;1147—1156.
Sychev D, Shikh N, Morozova T, et al. Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension. Pharmacogenomics and Personalized Medicine 2018, 11:157-165.
Mirzaev KB., Rytkin E., Ryzhikova KA., et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy 2018.
Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenomics and Personalized Medicine. 2018,11:43—49
Ivashchenko DV, Rudik AV, Poloznikov AA, et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018 May 4.
Fedorinov DS, Mirzaev KB, Mustafina VR, et al. Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA). Drug Metab P
Fedorinov DS, Mirzaev KB, Ivashchenko DV, et al. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 May 8.
Denisenko NP, Sychev DA, Sizova ZM, et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. 2018:11;107—112.